1. Search Result
Search Result
Results for "

rats model

" in MedChemExpress (MCE) Product Catalog:

139

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

9

Peptides

21

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3662

    Tyrosinase Cancer
    Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2 is a melanotropin, a melanocyte-stimulating hormone. Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2 stimulates tyrosinase and exhibits thermoregulatory effect in rats model .
    Ac-[Nle4,D-Phe7]-α-MSH (4-10)-NH2
  • HY-107482

    Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid

    GABA Receptor Neurological Disease
    Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
    Picamilon
  • HY-107482A

    Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate

    GABA Receptor Neurological Disease
    Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
    Picamilon sodium
  • HY-W098792

    Angiotensin Receptor Cardiovascular Disease
    Candesartan methyl ester is an antagonist for angiotensin II (AII) receptor with an IC50 of 0.11 μM. Candesartan methyl ester exhibits blood pressure lowering activity in rats models .
    Candesartan methyl ester
  • HY-105495

    Others Cardiovascular Disease
    Iliparcil has a potent antithrombotic activity in the Wessler model in rats. Iliparcil has oral activity .
    Iliparcil
  • HY-120481

    FAAH Neurological Disease
    JNJ-40413269 is an inhibitor for FAAH, that inhibits human FAAH and rats FAAH with IC50 of 28 nM and 270 nM. JNJ-40413269 exhibits analgesic efficacy in rat spinal nerve ligation model and exhibits good pharmacokinetic characteristics in rats .
    JNJ-40413269
  • HY-121080

    TRP Channel Neurological Disease
    AMG8163 is an orally active antagonist for TRPV1. AMG8163 inhibits Capsaicin (HY-10448)-induced flinch in rats models, and exhibits anti-hyperalgesia effects in multiple pain models .
    AMG8163
  • HY-15402

    BMS 207940

    Endothelin Receptor Cardiovascular Disease
    Edonentan (BMS 207940) is an antagonist for endothelin receptor (ETA receptor), with a Ki of 10 pM. Edonentan is metabolic stable, exhibits good pharmakokinetic characters in rats. Edonentan regulates the endothelin system, blocks the big Endothelin-induced pressor response in rats model .
    Edonentan
  • HY-W047156

    Biochemical Assay Reagents Metabolic Disease
    Allantoxanamide is a uricase inhibitor. Allantoxanamide-induced rats serve as animal models for studying purine biosynthesis, drug-induced hyperuricemia and hyperuricosuria, and related nephropathy .
    Allantoxanamide
  • HY-155042

    Angiotensin Receptor Cardiovascular Disease
    Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensin II receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .
    Antihypertensive agent 3
  • HY-123904

    iGluR Neurological Disease
    UoS12258 is a selective positive allosteric modulator of AMPA receptor. UoS12258 enhances AMPA receptor‐mediated synaptic transmission. UoS12258 improves performance in cognition rat models, including Scopolamine (HY-N0296)‐impaired rats and water maze learning and retention in aged rats .
    UoS12258
  • HY-103232

    mGluR Neurological Disease
    IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .
    IEM-1925 bromide
  • HY-118383

    Parasite Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Agathisflavone is a flavonoid with antioxidant, anti-inflammatory, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective activities. Agathisflavone can improve tissue repair in a spinal cord injury model in rats .
    Agathisflavone
  • HY-136880

    Sgd 195/78

    5-HT Receptor Cardiovascular Disease
    Flufylline shows antihypertensive properties in spontaneously hypertensive rats and display antagonism towards 5-HT receptors in various animal models. Flufylline can be used for cardiovascular disease research .
    Flufylline
  • HY-127152

    Pratorine

    Endogenous Metabolite Cardiovascular Disease
    Hippadine (Pratorine) is an alkaloid, which can be isolated from the plant Crinum macowanii. Hippadine exhibits heart-rate lowering and blood-pressure lowering effects in rats models with spontaneously hypertensive .
    Hippadine
  • HY-144289

    Glucokinase Metabolic Disease
    BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
    BMS-820132
  • HY-107176A

    HS-25

    Others Metabolic Disease
    Hyzetimibe is a cholesterol absorption inhibitor. Hyzetimibe blocks the intestinal absorption of cholesterol and phytol. Hyzetimibe is well tolerated in animal models, with an LDmax 2000 mg/kg in rats and an LDmax 500 mg/kg in rhesus monkeys .
    Hyzetimibe
  • HY-123556

    Monoamine Oxidase Neurological Disease
    SZV-558 is a potent and selective MAO-B inhibitor with IC50 values of 50 and 60 nM for rats and humans, respectively. SZV-558 can be used in studies of Parkinson's disease (PD) models .
    SZV-558
  • HY-W116576

    Drug Intermediate Cancer
    3-Methoxycatechol is intermediate for the antivascular agents combretastatin A-1 (HY-121993) and combretastatin B-1. 3-Methoxycatechol promotes esophageal carcinogenesis in rats models .
    3-Methoxycatechol
  • HY-114527

    Apoptosis Stearoyl-CoA Desaturase (SCD) Cancer
    TPMP-I-2 is an anticancer agent that induces cancer cell lines Apoptosis and decreases protein levels of stearoyl-CoA desaturase. TPMP-I-2 prolongs the survival time of nude rats in a simulated micrometastatic cervical cancer model and reduces tumor growth in a breast cancer model in nude mice combined with immunotoxins .
    TPMP-I-2
  • HY-B0235

    Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide
  • HY-106424

    Others Neurological Disease
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model .
    Soretolide
  • HY-B0235A

    Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide sodium
  • HY-B1573A

    AY-23,028; dl-Butaclamol hydrochloride

    Adrenergic Receptor Dopamine Receptor Neurological Disease
    (±)-Butaclamol hydrochloride (AY-23,028) is the antagonist for adrenergic receptor and dopamine receptor. (±)-Butaclamol hydrochloride antagonizes amphetamine or Apomorphine (HY-12723)-induced stereotyped behaviors and emesis, inhibits discriminative avoidance behavior, and induces catalepsy in rats models .
    (±)-Butaclamol hydrochloride
  • HY-149316

    E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC50 of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .
    Smurf1-IN-1
  • HY-P1694

    Bradykinin Receptor Cardiovascular Disease
    B4148 is a selective competitive bradykinin (BK) antagonist that significantly inhibits BK-induced hypotension in rats. In a rat model of endotoxin shock induced by Escherichia coli lipopolysaccharide, B4148 significantly attenuated the decrease in mean arterial blood pressure compared with the control group .
    B4148
  • HY-P10767

    Neurotensin Receptor Neurological Disease
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models .
    MD01-67
  • HY-116500A

    Calcium Channel Cardiovascular Disease
    AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes.
    AH-1058
  • HY-B2141

    NO Synthase HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Others Metabolic Disease
    Bendazol is an orally effective antihypertensive agent. Bendazol acts directly on vascular smooth muscle to dilate blood vessels and reduce peripheral resistance, thereby improving blood circulation. Bendazol significantly inhibits the development of myopia in rabbit models. Bendazol can regulate kidney function by increasing the activity of NO synthase in the rat model of nephrogenic hypertension. In addition, Bendazol has an effect on sexual behavior and spermatogenesis in male rats .
    Bendazol
  • HY-135026

    Adrenergic Receptor Neurological Disease
    DL-Norepinephrine tartrate is a neurotransmitter, which targets adrenergic receptors, and causes large-amplitude sleep-like electrical activity in the neocortex and suppresses electroencephalography (EEG) activity in the hippocampus. DL-Norepinephrine tartrate results in head shake, difficulty walking, and frequent posture changes in rats model .
    DL-Norepinephrine tartrate
  • HY-161942

    PCSK9 Metabolic Disease
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
    PCSK9-IN-31
  • HY-164605

    Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    (6S)-CP-470711 (Compound 8) is an inhibitor for sorbitol dehydrogenase, that inhibits human and rat SDH with IC50 of 19 nM and 27 nM. (6S)-CP-470711 ameliorates the Streptozotocin (HY-13753)-induced diabetes in rats models .
    (6S)-CP-470711
  • HY-170499

    BI02982816

    mGluR Neurological Disease
    VU6024578 (BI02982816) is a selective, orally active positive allosteric modulator (PAM) for metabotropic glutamate receptor (mGluR1), that activates human mGluR1 and rat mGluR1 with EC50 of 54 nM and 46 nM. VU6024578 exhibits antipsychotic activity in rats amphetamine-induced hyperactivity models and MK-801 (HY-15084B)-induced novel object recognition (NOR) models. VU6024578 is blood brain barrier penetrable .
    VU6024578
  • HY-118497

    Endothelin Receptor Cardiovascular Disease Metabolic Disease
    BMS 182874 is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research .
    BMS 182874
  • HY-B0235R

    Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide (Standard)
  • HY-103458

    Endothelin Receptor Cardiovascular Disease Metabolic Disease
    BMS 182874 hydrochloride is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 hydrochloride reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research .
    BMS 182874 hydrochloride
  • HY-170498

    GABA Receptor Neurological Disease
    GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pKi of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models .
    GABA-A Receptor Ligand-1
  • HY-153369

    Guanylate Cyclase Cardiovascular Disease Neurological Disease
    BAY-747 (BAY 1165747) is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
    BAY-747
  • HY-158030

    HDAC Neurological Disease
    HDAC6-IN-37 (compound W5) is an inhibitor of HDAC6 and has neuroprotective effects. HDAC6-IN-37 can restore the morphology of hippocampal neurons, reduce the expression of Aβ, Tau, and p-Tau proteins in the hippocampus of AD rats, and inhibit the formation of senile plaques and neurofibrillary tangles. Thus, HDAC6-IN-37 improves the Aβ/Cu 2+-induced AD model in rats, regulates oxidative stress status, and balances neurotransmitter disorders in brain tissue .
    HDAC6-IN-37
  • HY-171296

    p38 MAPK JNK Inflammation/Immunology
    p38 Kinase inhibitor 8 (Compound CCLXXVIII) is the orally active inhibitor for p38β and JNK2α2 with IC50s of 6.3 nM and 53.6 nM. p38 Kinase inhibitor 8 exhibits anti-inflammatory effect in rats collagen-induced arthritis models .
    p38 Kinase inhibitor 8
  • HY-124668

    CCR Inflammation/Immunology
    CCR1 antagonist 12 (Compound 12) is an antagonist for CCR1 with IC50 of 3 nM for human CCR1. CCR1 antagonist 12 inhibits CCL3-induced transwell chemotaxis with an IC50 of 0.009 µM. CCR1 antagonist 12 exhibits good pharmacokinetic characters in rats model .
    CCR1 antagonist 12
  • HY-115357

    PPAR Metabolic Disease
    BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .
    BMS711939
  • HY-114565

    Lipoxygenase Enterovirus Inflammation/Immunology
    LY221068 is an anti-oxidant and an orally active, potent inhibitor of iron-dependent lipid peroxidation and 5-lipoxygenase with antiinflammatory properties. LY221068 inhibits bone damage and paw swelling in the Freund's Complete adjuvant (HY-153808) induced arthritis (FCA) model of rats. LY221068 is promising for research of arthritis .
    LY221068
  • HY-144801A

    Potassium Channel Cardiovascular Disease
    DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005
  • HY-103327

    Cannabinoid Receptor Metabolic Disease
    MJ15 is a potent and selective CB1 receptor antagonist with a Ki of 27.2 pM and an IC50 of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice .
    MJ15
  • HY-162573

    Monoamine Oxidase Neurological Disease
    Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate .
    Monoamine Oxidase B inhibitor 5
  • HY-155823

    Cholinesterase (ChE) Neurological Disease
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .
    TZ4M
  • HY-173083

    Cannabinoid Receptor Neurological Disease
    MDA7 is the selective agonist for cannabinoid receptor 2 with EC50 of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with Ki of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .
    MDA7
  • HY-14923

    AVE 7688

    Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
    Ilepatril
  • HY-155822

    Cholinesterase (ChE) Neurological Disease
    TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .
    TZ3O